Medpace Holdings, Inc. $MEDP Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 33.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 177,853 shares of the company’s stock after selling 87,417 shares during the quarter. JPMorgan Chase & Co. owned about 0.63% of Medpace worth $91,445,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its stake in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Norges Bank acquired a new position in shares of Medpace in the second quarter worth $66,597,000. Arrowstreet Capital Limited Partnership increased its position in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the period. Clarkston Capital Partners LLC purchased a new stake in shares of Medpace during the second quarter worth $40,569,000. Finally, Bares Capital Management Inc. raised its stake in shares of Medpace by 319.2% in the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after acquiring an additional 119,608 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $455.15 on Wednesday. The business has a 50-day moving average of $517.88 and a two-hundred day moving average of $539.13. The company has a market capitalization of $12.92 billion, a price-to-earnings ratio of 29.75, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on MEDP shares. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Leerink Partners lowered their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a research note on Tuesday, February 10th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.